1. TREATMENT BASED ON TUMOR SIDEDNESS IN mCRC: THE EVIDENCE AND PRACTICAL APPLICATION

2. Introduction

3. Pathological Distinctions Between CRC Tumors

4. mCRC: Sidedness and Outcomes

5. Relevance of PTL in mCRC: What Is the Impact on Clinical Decisions?

6. Case 1: Left-Sided mCRC

7. Treatment Options for Left-Sided mCRC

8. Treatment-Related AEs Associated With EGFR Inhibitors

9. Chemotherapy ± Cetuximab in Patients With Resectable Colorectal Liver Metastasis: New EPOC Study

10. ESMO Consensus Guidelines for the Management of Patients With mCRC

11. NCCN Guidelines for the Treatment of Colon Cancer

12. Case 2: Right-Sided CRC

13. PTL Is Predictive of Treatment Response

14. EGFR Inhibitor-Associated Dermatologic Toxicities

15. Molecular Biomarker Testing for the Evaluation of CRC

16. Transverse CRC: Shared Embryology, Pathology, and Genetics

17. The Use of Tumor Sidedness as a Potential Surrogate Marker

18. Concluding Remarks

19. Abbreviations

20. Abbreviations (cont)